Guardant Health has acquired MetaSight Diagnostics for $59 million in upfront cash to bolster its multi-disease detection pipeline, the company said. The deal includes up to $90 million in payments tied to future commercial performance and regulatory approvals. MetaSight uses mass spectrometry multi-omics technology to find biomarkers associated with acute and chronic diseases in serum samples. Tests for colorectal cancer, an area of focus for Guardant, and liver disease-associated fibrosis were MetaSight’s two most advanced programs just before the acquisition.
Read the full article: Guardant Buys Metasight for $59M Upfront to Acquire Blood Test Tech //
Source: https://www.medtechdive.com/news/guardant-buys-metasight-for-59m-upfront-to-acquire-blood-test-tech/812795/